Ocera Therapeutics Company Profile (NASDAQ:OCRX)

About Ocera Therapeutics (NASDAQ:OCRX)

Ocera Therapeutics logoOcera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OCRX
  • CUSIP: N/A
  • Web: www.ocerainc.com
Capitalization:
  • Market Cap: $28.78 million
  • Outstanding Shares: 26,510,000
Average Prices:
  • 50 Day Moving Avg: $1.06
  • 200 Day Moving Avg: $1.11
  • 52 Week Range: $0.52 - $2.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.16
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $550,000.00
  • Price / Sales: 52.54
  • Book Value: $0.35 per share
  • Price / Book: 3.11
Profitability:
  • EBITDA: ($24,060,000.00)
  • Return on Equity: -175.02%
  • Return on Assets: -89.76%
Debt:
  • Current Ratio: 1.70%
  • Quick Ratio: 1.70%
Misc:
  • Average Volume: 235,392 shs.
  • Beta: 2.31
  • Short Ratio: 5.93
 

Frequently Asked Questions for Ocera Therapeutics (NASDAQ:OCRX)

What is Ocera Therapeutics' stock symbol?

Ocera Therapeutics trades on the NASDAQ under the ticker symbol "OCRX."

How were Ocera Therapeutics' earnings last quarter?

Ocera Therapeutics, Inc. (NASDAQ:OCRX) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01. View Ocera Therapeutics' Earnings History.

Where is Ocera Therapeutics' stock going? Where will Ocera Therapeutics' stock price be in 2017?

5 analysts have issued 12 month target prices for Ocera Therapeutics' shares. Their forecasts range from $1.00 to $10.00. On average, they anticipate Ocera Therapeutics' stock price to reach $4.50 in the next twelve months. View Analyst Ratings for Ocera Therapeutics.

Who are some of Ocera Therapeutics' key competitors?

Who are Ocera Therapeutics' key executives?

Ocera Therapeutics' management team includes the folowing people:

  • Linda S. Grais M.D., President, Chief Executive Officer, Director
  • Michael Byrnes, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
  • Stan Bukofzer M.D., Chief Medical Officer
  • Steven P. James, Lead Independent Director
  • Willard H. Dere M.D., Director
  • Nina S. Kjellson, Independent Director
  • Anne M. VanLent, Independent Director
  • Eckard Weber M.D., Independent Director

How do I buy Ocera Therapeutics stock?

Shares of Ocera Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocera Therapeutics' stock price today?

One share of Ocera Therapeutics stock can currently be purchased for approximately $1.09.


MarketBeat Community Rating for Ocera Therapeutics (NASDAQ OCRX)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Ocera Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ocera Therapeutics (NASDAQ:OCRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $4.50 (312.84% upside)
Consensus Price Target History for Ocera Therapeutics (NASDAQ:OCRX)
Price Target History for Ocera Therapeutics (NASDAQ:OCRX)
Analysts' Ratings History for Ocera Therapeutics (NASDAQ:OCRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017AegisReiterated RatingBuy$3.00LowView Rating Details
5/10/2017HC WainwrightReiterated RatingBuy$4.00HighView Rating Details
1/31/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
1/30/2017Stifel NicolausDowngradeBuy -> Hold$1.00N/AView Rating Details
10/24/2016Brean CapitalSet Price TargetBuy$10.00N/AView Rating Details
3/6/2016Cowen and CompanyReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Ocera Therapeutics (NASDAQ:OCRX)
Earnings by Quarter for Ocera Therapeutics (NASDAQ:OCRX)
Earnings History by Quarter for Ocera Therapeutics (NASDAQ OCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.24)($0.23)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.24)($0.28)ViewListenView Earnings Details
4/29/2016Q1($0.33)($0.36)$0.03 millionViewN/AView Earnings Details
3/3/2016Q415($0.33)($0.34)$0.02 millionViewN/AView Earnings Details
8/3/2015Q215($0.40)($0.46)$0.04 millionViewN/AView Earnings Details
4/30/2015Q115($0.29)($0.34)$0.03 millionViewN/AView Earnings Details
3/11/2015Q414($0.46)($0.28)$0.03 millionViewN/AView Earnings Details
11/13/2014Q314($0.50)($0.34)$0.23 millionViewN/AView Earnings Details
8/11/2014Q114($0.45)($0.46)$0.03 millionViewN/AView Earnings Details
5/8/2014($0.43)($0.27)$0.05 millionViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.48)$2.93 million$52.00 millionViewN/AView Earnings Details
11/13/2013Q3 13($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocera Therapeutics (NASDAQ:OCRX)
Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-0.94 EPS

Dividends

Dividend History for Ocera Therapeutics (NASDAQ:OCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ocera Therapeutics (NASDAQ:OCRX)
Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 20.25%
Insider Trades by Quarter for Ocera Therapeutics (NASDAQ:OCRX)
Institutional Ownership by Quarter for Ocera Therapeutics (NASDAQ:OCRX)
Insider Trades by Quarter for Ocera Therapeutics (NASDAQ:OCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2017Michael ByrnesCFOBuy3,000$1.28$3,840.00View SEC Filing  
12/7/2016Linda S GraisInsiderBuy7,000$2.14$14,980.00View SEC Filing  
10/13/2016Stan BukofzerInsiderBuy2,500$2.64$6,600.00View SEC Filing  
3/4/2016Linda S GraisCEOBuy3,000$3.19$9,570.00View SEC Filing  
1/22/2016Linda S GraisCEOBuy10,000$2.38$23,800.00View SEC Filing  
1/15/2016Gaurav AggarwalInsiderBuy10,000$2.15$21,500.00View SEC Filing  
1/15/2016Michael ByrnesCFOBuy3,500$2.07$7,245.00View SEC Filing  
6/23/2015Wendall WierengaDirectorBuy5,000$3.71$18,550.00View SEC Filing  
5/7/2015Rajiv PatniInsiderBuy5,050$3.97$20,048.50View SEC Filing  
5/6/2015Gaurav AggarwalInsiderBuy7,500$3.62$27,150.00View SEC Filing  
5/6/2015Linda S GraisCEOBuy30,000$3.73$111,900.00View SEC Filing  
5/6/2015Michael ByrnesCFOBuy2,500$3.61$9,025.00View SEC Filing  
10/1/2014Michael ByrnesVPBuy2,000$4.81$9,620.00View SEC Filing  
7/11/2014Linda S GraisCEOBuy10,000$5.93$59,300.00View SEC Filing  
7/11/2014Sharon TetlowCFOBuy3,000$5.83$17,490.00View SEC Filing  
7/15/2013Brian K HalakMajor ShareholderBuy995,618$6.03$6,003,576.54View SEC Filing  
7/15/2013Michael PowellDirectorBuy391,166$6.03$2,358,730.98View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ocera Therapeutics (NASDAQ:OCRX)
Latest Headlines for Ocera Therapeutics (NASDAQ:OCRX)
Source:
DateHeadline
streetinsider.com logoOcera Therapeutics (OCRX) to Present Three Posters, Oral Presentation on OCR-002 at AASLD - StreetInsider.com
www.streetinsider.com - October 21 at 7:18 AM
finance.yahoo.com logoOcera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®
finance.yahoo.com - October 21 at 7:18 AM
americanbankingnews.com logoOcera Therapeutics, Inc. (OCRX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 19 at 1:24 PM
americanbankingnews.com logoCritical Review: Chiasma (CHMA) & Ocera Therapeutics (OCRX)
www.americanbankingnews.com - October 6 at 2:08 AM
finance.yahoo.com logoWill Ocera Therapeutics Inc (OCRX) Need To Raise More Money?
finance.yahoo.com - October 5 at 6:37 PM
americanbankingnews.com logoOcera Therapeutics, Inc. (OCRX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 24 at 10:36 AM
americanbankingnews.com logoOcera Therapeutics, Inc. (OCRX) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - September 21 at 6:24 AM
americanbankingnews.com logoReviewing Baxalta (BXLT) & Ocera Therapeutics (OCRX)
www.americanbankingnews.com - September 20 at 12:16 AM
americanbankingnews.com logoFinancial Contrast: Catalyst Biosciences (CBIO) vs. Ocera Therapeutics (OCRX)
www.americanbankingnews.com - September 16 at 6:30 PM
americanbankingnews.com logoHead-To-Head Survey: Ocera Therapeutics (OCRX) & Its Peers
www.americanbankingnews.com - September 13 at 6:20 AM
americanbankingnews.com logo Analysts Anticipate Ocera Therapeutics, Inc. (OCRX) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - September 2 at 12:10 PM
americanbankingnews.com logoOcera Therapeutics, Inc. (OCRX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 10:56 AM
nasdaq.com logoOcera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver ... - Nasdaq
www.nasdaq.com - August 23 at 9:38 AM
finance.yahoo.com logoOcera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017
finance.yahoo.com - August 23 at 9:38 AM
americanbankingnews.com logoTransition Therapeutics (TTHI) versus Ocera Therapeutics (OCRX) Financial Contrast
www.americanbankingnews.com - August 19 at 2:26 AM
seekingalpha.com logoOcera Therapeutics: When A Drug Fails, But Actually Works - Seeking Alpha
seekingalpha.com - August 10 at 6:26 AM
americanbankingnews.com logoOcera Therapeutics Inc (NASDAQ:OCRX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 5 at 10:24 AM
americanbankingnews.com logoOcera Therapeutics, Inc. (NASDAQ:OCRX) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 2 at 6:00 PM
finance.yahoo.com logoOcera Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 6:32 AM
americanbankingnews.com logoFinancial Survey: Ocera Therapeutics (NASDAQ:OCRX) versus Strongbridge Biopharma PLC (SBBP)
www.americanbankingnews.com - July 27 at 8:11 PM
americanbankingnews.com logoOcera Therapeutics, Inc. (OCRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 11 at 10:32 AM
streetinsider.com logoOcera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with Cirrhosis - StreetInsider.com
www.streetinsider.com - June 2 at 9:02 PM
streetinsider.com logoOcera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with Cirrhosis
www.streetinsider.com - June 1 at 7:48 PM
nasdaq.com logoOcera Therapeutics to Host KOL Conference Call on Hepatic ... - Nasdaq
www.nasdaq.com - May 26 at 7:58 PM
seekingalpha.com logoOcera Therapeutics' (OCRX) CEO Linda Grais on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 13 at 8:17 AM
streetinsider.com logoOcera Therapeutics (OCRX) Reports Q1 Loss Per Share of $0.28, Offers Guidance
www.streetinsider.com - May 12 at 12:30 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Wells Fargo, HanesBrands ... - Nasdaq
www.nasdaq.com - April 13 at 11:47 PM
streetinsider.com logoAfter-Hours Stock Movers 04/12: (OCRX) (AAOI) (HBI) Higher; (SRNE) (DMPI) (PIR) Lower (more...) - StreetInsider.com
www.streetinsider.com - April 13 at 8:04 AM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
biz.yahoo.com - March 31 at 7:05 PM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 14 at 6:30 PM
nasdaq.com logoMid-Aternoon Market Update: Crude Oil Down 1.5%; Citi Trends Shares Rise On Earnings Beat
www.nasdaq.com - March 10 at 8:45 PM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - March 10 at 9:19 AM
finanznachrichten.de logoGainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM...
www.finanznachrichten.de - March 9 at 11:51 PM
seekingalpha.com logoOcera Therapeutics (OCRX) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 9 at 6:50 PM
baystreet.ca logoCrushed in January, Shares of Ocera Therapeutics Bounce Back on Trial Data
www.baystreet.ca - March 9 at 12:47 AM
streetinsider.com logoOcera Therapeutics (OCRX) Says Data Confirms OCR-002 Lowered Ammonia, Correlated Statistically with Clinical Improvement in Patients with HE
www.streetinsider.com - March 8 at 7:45 PM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - March 8 at 9:25 AM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocera ...
www.businesswire.com - February 2 at 7:52 PM
streetinsider.com logoForm 8-K Ocera Therapeutics, Inc. For: Jan 30 - StreetInsider.com
www.streetinsider.com - January 31 at 8:01 AM
streetinsider.com logoJMP Securities Downgrades Ocera Therapeutics (OCRX) to Market Perform - StreetInsider.com
www.streetinsider.com - January 31 at 8:01 AM
rttnews.com logoOcera Therapeutics Inc. (OCRX) Sank To A New Low On Phase 2 Study Results - RTT News
www.rttnews.com - January 31 at 8:01 AM
streetinsider.com logoPre-Open Movers 01/30: (CALA) (DHT) (XXIA) Higher; (OCRX) (RGLS) (TPX) Lower (more...)
www.streetinsider.com - January 31 at 12:43 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Rite Aid, Calithera, Ocera, Ixia - Nasdaq
www.nasdaq.com - January 30 at 7:40 PM
seekingalpha.com logoOcera's lead product candidate flunks mid-stage HE study; shares plummet 59% premarket - Seeking Alpha
seekingalpha.com - January 30 at 7:40 PM
streetinsider.com logoOcera's (OCRX) Phase 2b Study of OCR-002 in Hepatic Encephalopathy Wasn't Statistically Significant in Primary and Secondary Endpoints
www.streetinsider.com - January 30 at 8:48 AM
us.rd.yahoo.com logo7:00 am Ocera Therapeutics announces top-line results for Phase 2b study in Hepatic Encephalopathy; primary and secondary endpoints showed trend and dose-related clinical benefit although not statistically significant (shares halted)
us.rd.yahoo.com - January 30 at 8:48 AM
biz.yahoo.com logoOCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - January 9 at 7:41 PM
streetinsider.com logoOcera Therapeutics (OCRX) Announces Positive Phase 1 Clinical Study of Orally-Administered OCR-002
www.streetinsider.com - January 6 at 7:42 PM
streetinsider.com logoOcera Therapeutics (OCRX) Announces Positive Phase 1 Clinical Study of Orally-Administered OCR-002 - StreetInsider.com
www.streetinsider.com - January 5 at 11:07 PM

Social

Chart

Ocera Therapeutics (OCRX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.